TrkB (Tropomyosin Receptor Kinase B) modulator therapy represents a promising disease-modifying approach for Parkinson's disease that aims to enhance neurotrophic support to dopaminergic neurons in the substantia nigra pars compacta. The TrkB receptor is the primary signaling receptor for brain-derived neurotrophic factor (BDNF), a critical neurotrophin that supports neuronal survival, differentiation, and synaptic plasticity.
The therapeutic rationale for TrkB modulation in PD is strongly supported by evidence showing that BDNF levels are reduced in the brains of Parkinson's disease patients[1]. By enhancing TrkB signaling, these therapies aim to protect remaining dopaminergic neurons, promote regeneration of neural circuits, and potentially slow or halt disease progression.
The BDNF-TrkB signaling pathway is fundamental to dopaminergic neuron survival:
| Property | Description |
|---|---|
| Gene | NTRK2, chromosome 9q21 |
| Protein | TrkB (790 amino acids) |
| Molecular weight | ~140 kDa (full-length isoform) |
| Isoforms | Full-length (TrkB-FL), TrkB-T1 (truncated) |
| Ligands | BDNF, NT-4, NT-3 (lower affinity) |
TrkB activation triggers three major downstream signaling cascades:
PI3K/Akt Pathway: The primary pro-survival pathway, activating mTOR and inhibiting pro-apoptotic proteins like BAD and caspase-9. This pathway is critical for preventing dopaminergic neuron apoptosis.
MAPK/ERK Pathway: Regulates gene expression through transcription factors (CREB, Elk-1), promoting synaptic plasticity, dendritic growth, and long-term potentiation. Essential for circuit repair in PD.
PLCγ Pathway: Modulates intracellular calcium levels, affecting neurotransmitter release and synaptic transmission. Relevant for restoring dopaminergic signaling.
Multiple lines of evidence support BDNF deficiency in PD:
Small molecule TrkB agonists represent an attractive approach for oral bioavailability and systemic delivery:
| Compound | Company | Stage | Notes |
|---|---|---|---|
| 7,8-DHF | Research | Preclinical | Natural flavonoid, TrkB agonist |
| TSF100407 | Research | Preclinical | Blood-brain barrier penetrant |
| BDNF mimetic peptides | Research | Preclinical | Peptide-based TrkB activation |
7,8-Dihydroxyflavone (7,8-DHF): A natural flavonoid that acts as a potent TrkB agonist. Preclinical studies in PD models show:
Viral vector-mediated BDNF delivery aims for sustained neurotrophic support:
AAV-BDNF: Adeno-associated virus vectors carrying the BDNF gene have shown promise in preclinical PD models[2]. The approach involves:
AAV-Neurturin (CERE-120): Although not directly targeting TrkB, neurturin is a TrkB ligand that has been tested in PD clinical trials[3]. The trial provided important lessons about delivery and target validation.
Cell therapy approaches for BDNF delivery:
Monoclonal antibodies targeting TrkB are being developed:
Several approaches can enhance TrkB signaling indirectly:
| Approach | Mechanism |
|---|---|
| Exercise | Increases endogenous BDNF expression |
| Deep brain stimulation | Upregulates BDNF in target regions |
| Dietary approaches | Ketogenic diet, intermittent fasting increase BDNF |
| Model | Intervention | Outcome |
|---|---|---|
| 6-OHDA rat | AAV-BDNF | Protected dopaminergic neurons, improved motor function[4] |
| MPTP mouse | 7,8-DHF | Reduced dopaminergic neuron loss |
| MPTP primate | Lentiviral GDNF | Protected neurons, preserved function[5] |
Direct TrkB agonist clinical trials in PD remain limited. However:
Several academic and industry programs are actively developing TrkB-targeted therapies:
TrkB activation provides neuroprotection through multiple mechanisms:
Anti-apoptotic signaling: Akt activation leads to phosphorylation and inactivation of pro-apoptotic proteins (BAD, caspase-9), preventing dopaminergic neuron death.
Enhanced protein synthesis: mTOR activation promotes local translation of survival proteins at synapses, supporting synaptic maintenance.
Synaptic plasticity: ERK pathway activation leads to CREB-mediated gene expression that supports synaptic formation and function.
Neuroinflammation modulation: TrkB signaling can modulate microglial activation, reducing harmful neuroinflammation in PD.
As with other protein therapeutics, BDNF and TrkB modulators face significant delivery obstacles:
| Factor | TrkB Modulation | GDNF-family | NGF |
|---|---|---|---|
| Primary receptor | TrkB | GFRα1/Ret | TrkA |
| Clinical trials in PD | Limited | Yes (CERE-120) | No |
| Delivery challenge | High | High | High |
| Dopamine neuron support | Strong | Strong | Limited |
TrkB modulation may be combined with:
Mogi M, et al. Brain-derived neurotrophic factor concentration in the cerebrospinal fluid of patients with Parkinson's disease. Neuroscience Letters. 1999. ↩︎ ↩︎
Nagahara AH, Tuszynski MH. Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nature Reviews Drug Discovery. 2011. ↩︎
Bartus RT, Johnson EM Jr. Clinical tests of neurotrophic factors for treating Parkinson's disease. Movement Disorders. 2017. ↩︎ ↩︎
Levivier M, Przedborski S. Neural transplants and neurotrophic factors. Neurobiology of Disease. 1998. ↩︎
Kordower JH, et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science. 2000. ↩︎